This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
IM Anderson (2008). Commentary on ‘Re-evaluation of the efficacy and tolerability of venlafaxine versus SSRI: meta-analysis’ by Weinmann et al. Psychopharmacology 196, 521–522.
P Auquier , S Robitail , P-M Llorca , B Rive (2003). Comparison of escitalopram and citalopram efficacy: a meta-analysis. International Journal of Psychiatry in Clinical Practice 7, 259–268.
JP Boulenger , AKT Huusom , I Florea , T Baekdal , M Sarchiapone (2006). A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Current Medical Research and Opinion 22, 1331–1341.
WJ Burke , I Gergel , A Bose (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Journal of Clinical Psychiatry 63, 331–336.
L Colonna , HF Andersen , EH Reines (2005). A randomised, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Current Medical Research and Opinion 21, 1659–1668.
MA Hamilton (1960). A rating scale for depression. Journal of Neurological and Neurosurgical Psychiatry 23, 56–62.
S Kasper , D Baldwin , S Larsson Lönn , JP Boulenger (2009). Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology 19, 229–237.
I Kirsch , BJ Deacon , TB Huedo-Medina , A Scoboria , (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine. Published online: 26 February 2008. doi:10.1371/journal.pubmed.0050045.
SH Kennedy , HF Andersen , ME Thase (2009). Escitalopram in the treatment of major depressive disorder: a meta-analysis. Current Medical Research and Opinion 25, 161–175.
I Kirsch , TJ Moore , A Scoboria , SS Nicholls (2002). The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention & Treatment 5, Article 23.
V Lalit , A Prakash , H Rajendra , M Anukant , et al. (2004). Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar depression. Indian Journal of Psychiatry 46, 333–341.
RW Lam , HF Andersen (2006). The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 39, 180–184.
C Lançon , C Sapin , I Note , J Farisse (2006). Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. International Journal of Psychiatry in Clinical Practice 10, 131–137.
U Lepola , A Wade , HF Andersen (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. International Clinical Psychopharmacology 19, 149–155.
UM Lepola , H Loft , EH Reines (2003). Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 18, 211–217.
P-M Llorca , J-M Azorin , N Despiegel , P Verpillat (2005). Efficacy of escitalopram in patients with severe depression: a pooled analysis. International Journal of Clinical Practice 59, 268–275.
J Li , WW Shen , Y Liu , L Xu , et al. (2006). The effectiveness and safety of escitalopram in the treatment of major depression: a randomized double-blind active-drug controlled trial [in Chinese]. Chinese Journal of Evidence-based Medicine [Zhongguo xunzheng yixue zazhi] 6, 552–556.
H Melander , T Salmonson , E Abadie , B van Zwieten-Boot (2008). A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. European Neuropsychopharmacology 18, 623–627.
SA Montgomery , HF Andersen (2006). Escitalopram versus venlafaxine XR in the treatment of depression. International Clinical Psychopharmacology 21, 297–309.
SA Montgomery , M Åsberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382–389.
SA Montgomery , DS Baldwin , P Blier , NA Fineberg , et al. (2007). Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology 22, 323–329.
SA Montgomery , HJ Möller (2009). Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? International Clinical Psychopharmacology 24, 111–118.
N Moore , H Verdoux , B Fantino (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International Clinical Psychopharmacology 20, 131–137.
VY Yevtushenko , AI Belous , YG Yevtushenko , SE Gusinin , et al. (2007). Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clinical Therapeutics 29, 2319–2332.